GE Healthcare

To see an up-to date selection of historical analyses and insights on GE Healthcare, visit our new, dynamically updated Company Summary report pages for GE Healthcare.

As a Guest User, you will have FREE access to a selection of historical analyses and insights from EvaluatePharma®.

How to access FREE content

  • Search the content using the search box at the top of every page
  • Browse content by Company, Product, Generic Name, Therapeutic Category or Indication using the "Browse By" link from the navigation bar
  • Create Peer Groups to compare Companies using the "Peer Groups" link from the navigation bar

Register for FREE to access even more content including 2007 Product Sales and Rankings.

A small selected sample of reports and related news headlines for GE Healthcare are available below. Free sample reports are also available for other Companies.

To find out how you can access more detailed information on GE Healthcare, or on any other Company covered by EvaluatePharma® Contact Us today.

NEWS - Selected Product News Headlines (as of 11 June 2008)
Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A   (Repligen)   (Invalid Date)
Photocure Received Positive Response from FDA on the New Drug Application (NDA) for Hexvix® for Detection of Bladder Cancer   (Photocure)   (Invalid Date)
FDA Advisory Committee Voted Favourably to Hexvix® Application in USA   (Photocure)   (Invalid Date)
NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico   (Novavax)   (Invalid Date)
FDA has Posted an Advisory Committee meeting with Photocure to Discuss Hexvix® NDA   (Photocure)   (Invalid Date)
Novavax Launches Pivotal Clinical Study of Novel 2009 H1N1 VLP Flu Vaccine in Mexico   (Novavax)   (Invalid Date)
Hexvix® has been Granted Priority Review by the FDA   (Photocure)   (Invalid Date)
FDA Advisory Committee Recommends DaTSCAN(™) (Ioflupane I 123 Injection)   (GE Healthcare)   (Invalid Date)
Photocure Submits Application for Marketing Approval for Hexvix® in USA to the FDA   (Photocure)   (Invalid Date)
Hexvix® Cystoscopy Detects More Cancer and Reduces Recurrence   (Photocure)   (Invalid Date)
InnoPharmax Announced the ANDA Approvals of Immurin® Soft Gelatin Capsule 100 mg and Gadoscan® I.V. Injection   (Innopharmax)   (Invalid Date)
GE Healthcares Application for DaTSCAN (Loflupane I123 Injection) Accepted by the FDA for Priority Review   (GE Healthcare)   (Invalid Date)
DRAXIMAGE®’s Generic Sestamibi Approved for Launch in USA   (Jubilant Organosys)   (Invalid Date)
GE Healthcare Announces Data from Phase III Study of Adreview in Heart Failure Patients   (GE Healthcare)   (Invalid Date)
Fluorescence Cystoscopy Improves Detection and Resection of Papillary Bladder Cancer Lesions and Reduces Early Recurrences   (Photocure)   (Invalid Date)
GE’s First Portable ECG, “Medical Texting,” Arrives in US   (GE Healthcare)   (Invalid Date)
Jubilant Receives Approvals for Sestamibi in Canada   (Jubilant Organosys)   (Invalid Date)
Novavax Presents Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program at World Health Organization Conference   (Novavax)   (Invalid Date)
Acusphere Announces Change In Imagify Regulatory Strategy and Deferral of Near-Term Contractual Cash Payments   (Acusphere)   (Invalid Date)

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts.

Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®.

Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis.

Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.